Drugs / Ferucarbotran
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00453817 | Jun 2005 → Jun 2010 | type 1 diabetes mellitus | University Hospital, Geneva | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00886444 | Mar 2009 → Mar 2010 | acute myocardial infarction | Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ferucarbotran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00453817 ↗ |
| Modality | Diagnostic / imaging agent | “ferucarbotran (iron-based MRI contrast agent)” NCT00453817 ↗ |
| Route | Intravenous | “single time intravenous bolus injection” NCT00886444 ↗ |